CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-23 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −43 | $41.05 | $2K | 456,767 |
| 2026-09-08 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −7,141 | $45.56 | $325K | 460,046 |
| 2026-09-08 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −1,069 | $46.01 | $49K | 458,977 |
| 2026-08-25 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −18,921 | $49.57 | $938K | 467,187 |
| 2026-08-25 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −20,799 | $50.31 | $1.0M | 212,063 |
| 2026-08-25 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −16,201 | $51.06 | $827K | 195,862 |
| 2026-08-24 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −13,160 | $50.00 | $658K | 232,862 |
| 2026-08-19 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −404 | $49.90 | $20K | 246,022 |
| 2026-08-11 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −3,664 | $46.90 | $172K | 511,402 |
| 2026-08-11 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −19,500 | $48.04 | $937K | 491,902 |
| 2026-08-11 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,794 | $48.62 | $282K | 486,108 |
| 2026-08-10 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −14,171 | $45.97 | $651K | 523,436 |
| 2026-08-10 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −8,370 | $46.75 | $391K | 515,066 |
| 2026-07-27 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,203 | $42.11 | $93K | 537,614 |
| 2026-07-27 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −7 | $42.74 | $299 | 537,607 |
| 2026-07-14 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,481 | $39.72 | $218K | 542,546 |
| 2026-07-14 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,729 | $40.57 | $111K | 539,817 |
| 2026-06-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −1,900 | $40.09 | $76K | 158,014 |
| 2026-06-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −3,792 | $41.39 | $157K | 154,222 |
| 2026-06-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −3,308 | $42.17 | $140K | 150,914 |
Page 2 of 10 · 186 trades